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Sarcopenia is prevalent in older persons and is a risk factor for falls, fractures, and mortality.
The aim of this study was to determine a) the feasibility of determining sarcopenia in patients
with acute hip fracture, b) the prevalence of sarcopenia and c) associations of sarcopenia
with nutritional status and comorbidities.
Methods
A multicenter cross-sectional study on sarcopenia in male and female patients with acute
hip fracture. Participants were previously ambulatory and living in the community. Sarcope-
nia was assessed postoperatively with muscle mass estimated by anthropometry using tri-
ceps skinfold, arm circumference, height, weight and sex. Grip strength was measured by
Jamar dynamometer and pre-fracture mobility was by self-report using the New Mobility
Score.
Results
Out of 282 patients, 202 were assessed for sarcopenia of whom 74 (37%) were diagnosed
as sarcopenic. Sarcopenia was associated with age, odds ratio (OR) 1.4 per 5 years, 95%
confidence interval (CI) [1.1, 1.8], ASA Physical Status Classification System score, OR 2.3
per point, 95% CI [1.3, 4.3] and number of medications at discharge, OR 1.2 per medication,
95% CI [1.0, 1.3] and inversely associated with BMI, OR 0.8, 95% CI [0.7, 0.9] and serum
albumin, OR 0.9, 95% CI [0.8,1.0].
Conclusions
Thirty-seven percent of assessed subjects were diagnosed with sarcopenia. Our data dem-
onstrates that the prevalence of sarcopenia is associated with older age, malnutrition and
comorbidities. Determining sarcopenia at the bedside was feasible in postoperative hip
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fracture patients by using grip strength, estimation of muscle mass by anthropometry and
self-reported mobility.
Introduction
Sarcopenia is a syndrome characterized by reduced muscle mass and reduced muscle function
and an increased risk of disability and death [1]. Sarcopenia has recently been recognized as an
independent condition with an International Classification of Disease Code [2]. Sarcopenia is
a well-known risk factor for both falls and fractures: Reduced muscle strength makes it more
difficult to regain lost balance and decreases the mechanical loading of the skeleton leading to
reduced adaptive bone remodeling [3, 4]. Half of all hip fracture survivors will develop perma-
nent impairments in mobility and 10–20% will become institutionalized [5]. The prevalence of
sarcopenia in hip fracture patients is 17–74%, depending on population and definition of sar-
copenia [6–8]. Norway has one of the highest rates of hip fracture in the world [9] and it is esti-
mated that 4–5% of all deaths in the Norwegian population aged 50+ are attributable to hip
fractures [10]. The reasons for this are unknown and sarcopenia is a candidate for explaining
some of this excess risk. There has been only moderate improvement in the outcomes of
patients with hip fracture since the 1960s [11]. Studies indicate that better outcomes are possi-
ble by involving geriatricians and increasing the intensity of rehabilitation efforts [12, 13].
Exercise and nutritional interventions are important interventions for sarcopenia [14] and in
rehabilitation after hip fracture [15]. Smoking cessation and reduction of harmful alcohol
intake can possibly reduce sarcopenia [16–18] and the risk of hip fracture [19–22]. There is no
consensus on how sarcopenia should be operationalized. The three main methods are: low
muscle mass as recommended by Janssen et al [23], low muscle mass with one of reduced
physical performance or muscle strength, as recommended by the European Working Group
on Sarcopenia in Older People (EWGSOP) [1] and low muscle mass and low grip strength, as
recommended by the Foundation for the National Institutes of Health Biomarkers Consor-
tium Sarcopenia Project [24]. These recommendations are based on studies on older people
living in the community. Investigating the feasibility of determining sarcopenia in acute hip
fracture patients is necessary before assessment of sarcopenia can be introduced in clinical
practice. The aims of this study are to:
1. assess the feasibility of determining sarcopenia in acute hip fracture patients.
2. determine the prevalence of sarcopenia and investigate how sarcopenia is associated with
risk factors for adverse clinical outcomes: older age and male sex [10], nutritional risk and
low albumin, low vitamin D, low body mass index (BMI) [25], comorbidities and polyphar-
macy, and impairments in activities of daily living [26].
3. Investigate the separate associations of muscle mass, grip strength and mobility with the
same risk factors.
Materials and methods
This is a cross-sectional study on sarcopenia in patients with hip fracture. Patients were
included in the immediate postoperative period at three hospitals in Norway, 2011–2013.
Patients eligible for participation were 65 years or older, ambulatory before the hip fracture
and willing to provide written informed consent. Permanent residents of nursing homes,
patients who were medically unstable or had a life expectancy of less than 3 months, were
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excluded. Collection of data was by the authors or research personnel, with different teams at
the different hospitals. All personnel received training and guidance from the first author
(OMS). Research staff were not present on the wards at all times, such as during weekends or
holidays. Pre-fracture independence in activities of daily living (meals, bathing, grooming,
dressing, continence, toileting, transferring and ambulation) was determined by the modified
Barthel index (B-ADL), a summary score with a range 0–20 [27]. Nutritional risk was assessed
using the Nutritional Risk Screening Score 2002 (NRS 2002) [28]. The NRS 2002 is a screening
tool for identifying hospitalized patients likely to benefit from nutritional interventions. It is
scored 0–3 points for nutritional state, 0–3 points for illness severity and an additional point if
aged>70 years, for a total of score 0–7. Patients with hip fracture will typically be given one
point for illness severity. Serum albumin and 25-OH vitamin D was measured in the fasting
state, preoperatively at one hospital and postoperatively at two hospitals. Participants use of
supplemental vitamin D (as tablets or cod liver oil) was determined by food frequency ques-
tionnaire and chart review. Comorbidities were assessed by chart review for determining the
Charlson index [29]. The Charlson index is a list of chronic diseases, weighted by severity,
that has been found to predict mortality. The American Society of Anesthesiologists Physical
Status Classification System (ASA) score is a grading system of the preoperative health of sur-
gical patients, range 1–5 [30]. The number of medications used regularly and as needed was
assessed at discharge.
Determining sarcopenia
Participants were identified as being “not sarcopenic” or “sarcopenic” using the criteria recom-
mended by the EWGSOP [1]. To be categorized as sarcopenic participants had to have low
muscle mass and one of either low grip strength or low mobility. Total body muscle mass was
estimated by anthropometry by the method of Heymsfield et al. [31] using gender, height, arm
circumference and triceps skinfold. Arm circumference was measured on the right arm at the
mid-point between the acromion and olecranon process with the arm hanging down. Triceps
skinfold was measured on the posterior aspect of the same arm at the same level using a skin-
fold caliper (Harpenden, Baty International, Great Britain). Measurements were repeated until
two readings were within 1mm. The values for total body muscle mass were converted to ap-
pendicular lean mass (ALM) using model 1 of Kim et al [32]. It has previously been reported,
using data from this study, that anthropometry by the Heymsfield method was able to identify
patients with low muscle mass, compared to Dual Energy X-ray absorptiometry (DXA) [33].
Patients were weighed in light clothing using the scales available on the hospital wards. Height
was measured by wall-mounted stadiometer, except for a few cases where the patient was
unable to stand. In those cases, height measured at other time-points, self-reported height or
the distance from heel to crown while lying in bed was used. Cut-points for low muscle mass
were chosen based on the recommendations of the EWGSOP [1], ALM divided by height
squared,7.25 kg.m-2 for men and5.67 kg.m-2 for women.
Grip strength was measured three consecutive times in one hand and immediately after-
ward on the other hand with a Jamar Hydraulic Dynamometer (Sammons Preston, USA)
while the patient was sitting in bed or on a chair, with the elbow flexed, the wrist in the neutral
position, and with verbal encouragement. There was a brief interval between attempts while
the dynamometer was repositioned. The single best value of all six measurements was used.
Low grip strength was defined as 30kg for men and 20kg for women, as recommended by
the EWGSOP[1]. Grip strength and muscle mass was determined at daytime in the mainly
bed-bound participants without consideration of meals, recent physical activity, bladder void-
ing or hydration.
Sarcopenia in patients with hip fracture
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Mobility was determined by the New Mobility Score (NMS). The NMS assesses mobility in
the two weeks prior to the fracture by interview. It ranges 0–9; a score of zero indicates that the
person is not ambulatory and nine indicates an ability to walk without assistance while shop-
ping. The NMS predicts physical performance and mortality after hip fracture [34–36]. Low
mobility was defined as NMS <5, based on the cut-point recommended for predicting mortal-
ity after hip fracture [34]. Anthropometry for determining muscle mass was chosen because it
is an established technique for determining body composition [37], is in common use [38],
inexpensive and more easily performed on patients with pain on mobilization compared to
DXA. Estimating muscle mass by anthropometry in patients with acute hip fracture requires
some effort, mainly in determining height and weight. Grip strength is quickly measured, but
requires an alert patient able to take instruction and with reasonable hand function. The NMS
was chosen because it was assumed that some participants would be unable to perform tests of
physical performance and because self-reported mobility has been found to have similar psy-
chometric and predictive properties to objective tests [39]. Mobility by the NMS can be deter-
mined in a minute in a bed-bound patient, as long as the patient or proxy is able to answer
questions about pre-fracture mobility.
Ethics
All participation was by written, informed consent. Patients were included in the postoperative
phase as pain and anxiety is less after surgery. Participating hospitals, Haraldsplass Deaconess
Hospital, Haukeland University Hospital and Diakonhjemmet Hospital, and the Regional
Committee on Medical and Health Research Ethics approved the study (2011/1322/REK sør-
øst B). The study was conducted according to the principles of the Declaration of Helsinki
[40].
Statistical analysis
Participants were described according to sarcopenia status with median and interquartile
range (IQR) or mean and standard deviation (SD) and the differences between groups were
analyzed with the Mann–Whitney–Wilcoxon test. The association between sarcopenia as
dependent variable and the different risk factors as independent variables was analyzed in sep-
arate logistic regression analyses with odds ratios (OR) and 95% confidence intervals (95%
CI). Separate analysis was also performed with low muscle mass, low grip strength and low
mobility as dependent variables. Regression analyses were adjusted for age, sex and BMI and
analysis of vitamin D was additionally adjusted for using supplemental vitamin D. Age, sex
and BMI were included in the models because they are established associations of grip strength
and muscle mass [41]. P0.05 was considered significant. Analysis was by Stata 14.0 (Stata
Corp., USA)
Results
Of the included 282 patients with acute hip fracture, low muscle mass was found in 61% (118/
194), low grip strength in 52% (116/222), and low mobility in 8% (20/244). Sarcopenia preva-
lence was 37% (74/202). Fig 1 illustrates which participants were assessed for mobility, grip
strength and muscle mass. Participants with sarcopenia were older, had evidence of nutritional
risk as indicated by lower BMI, lower albumin and higher scores on the NRS 2002. Participants
with sarcopenia were also characterized by longer hospital stay, higher ASA score at operation,
used a greater number of medications at discharge and had more impairments in activities of
daily living before the hip fracture (Table 1). Participants with missing values for sarcopenia
status had lower B-ADL scores compared to those who did not have missing values, and
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women with missing values had lower grip strength and mobility. Reasons for missing values
included patients being too ill for or refusing specific examinations, or that they were dis-
charged before the data collection was completed. Intracapsular fractures constituted 59% of
the fractures. For 8% of patients this was their second hip fracture. Grip strength and ALM
were determined at a median of 4 days after surgery, the interquartile range was 3 to 6 days,
and the total range was from the day before surgery to 24 and 34 days after surgery, respec-
tively. Supplemental vitamin D was used by 50% and was associated with a significantly higher
serum vitamin D, 63 (SD 26) versus 47 (SD 23) 10−6 mol.m-3 (nmol/L). During the period of
inclusion, 1592 patients were admitted for hip fracture surgery at the three hospitals.
The results of regression analysis for sarcopenia are presented in Fig 2 and Table 2. In
adjusted analysis, sarcopenia was positively associated with age, OR 1.4 for each 5-year
increase, 95% CI [1.1, 1.8], ASA score, OR 2.4, 95% CI [1.3, 4.3], and number of medications
at discharge, OR 1.2, 95% CI [1.0, 1.3]. BMI, OR 0.8, 95% CI [0.7, 0.9] and serum albumin, OR
0.9 95% CI [0.8, 1.0], were associated with not having sarcopenia.
Results for the adjusted regression analyses for low muscle mass, low grip strength and low
mobility are presented in Table 3. Low muscle mass, using sex-specific cut-points, was associ-
ated with male gender, OR 5.4, 95% CI [1.8, 15.8]. BMI and albumin were negatively associated
with low muscle mass. Low grip strength was associated with increasing age and ASA score
and associated with lower BMI and albumin. Low mobility was associated with age and num-
ber of medications at discharge and negatively associated with impairments in activities of
daily living.
Discussion
The aims of this study were to determine the feasibility of identifying sarcopenia in acute hip
fracture patients, estimate the prevalence of sarcopenia and the associations between sarcope-
nia and risk factors for adverse clinical outcomes after hip fracture. Two hundred and eighty-
two participants were included and sarcopenia status was determined in 202. Determining sar-
copenia status using the bedside methods of anthropometry, grip strength and the NMS was
feasible, is relevant to clinicians as a bedside tool, and is possible to implement on busy hospital
wards. The rate of 28% of unsuccessful assessments for sarcopenia indicates that further
improvement is warranted. Feasibility would be improved if muscle mass could be estimated
without determining height or weight. Malmstrom and Morley have recommended the simple
screening tool SARC-F as method to diagnose sarcopenia [42]. The SARC-F is a questionnaire
containing 4 questions about physical performance and one question about falls in the last
Fig 1. Participants assessed for mobility, grip strength and muscle mass.
https://doi.org/10.1371/journal.pone.0184780.g001
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year. Future research should investigate the role of the SARC-F in patients with hip fracture.
In the present study, sarcopenia was determined by anthropometry, which is considered a less
precise method compared to DXA or bioelectrical impedance analysis. Anthropometry is ade-
quate at identifying low muscle mass [43] and is able to identify increased mortality risk in
males [44, 45]. Because of pain and severe mobility impairment, it is difficult to measure mus-
cle mass by DXA in patients with hip fracture. Compared to anthropometry, DXA is more
expensive, requires bulky equipment, takes longer time to do, and requires more trained per-
sonnel. DXA estimates of muscle mass are sensitive to acute changes in muscle water content,
such as seen with changes in muscle glycogen or creatinine due to feeding or dehydration [46].
A strength of the present study is that participants were recruited at three separate hospitals.
This reduced the influence of investigator specific factors such as confirmation bias and
reduced the influence of hospital related factors such as differences in quality of care, differ-
ences in catchment populations, or selective recruitment processes. A multi-center study is
leads to greater generalizability of results. A weakness of the multi-center design was less con-
trol of the conduct of the study, leading to loss of information on participants who were
screened but not included and missing values.
Three recent cross-sectional studies have investigated sarcopenia in acute hip fracture
patients using the EWGSOP framework. There was great variation in the prevalence of
Table 1. Characteristics of participants by sarcopenia status.
Not sarcopenic, n = 128 Sarcopenic, n = 74
Age, years [IQR] 77.5 [70,5–85] n = 128 82 [76–86] n = 74**
Female, N (%) 99 (77) n = 128 53 (72) n = 74
Length of hospital stay, days [IQR] 6 [5–8] n = 128 7.5 [6–11] n = 74**
BMI, kg.m-2 [IQR] 25.3 [22.7–28.0] n = 110 22.0 [19.5–24.2] n = 67**
NRS 2002 [IQR] 2 [2–2] n = 117 2 [2–3] n = 70**
Albumin, kg.m3 (SD) 35.9 (5.2) n = 113 32.6 (6.3) n = 59**
User of vitamin D supplement, N (%) 60 (50) n = 119 31 (46) n = 56
Vitamin D, 10−6 mol.m-3 [IQR] 53 [34–75] n = 111 48 [31–66] n = 64
Charlson index [IQR] 0.5 [0–1] n = 128 1 [0–2] n = 74
ASA score [IQR] 2 [2–3] n = 128 3 [2–3] n = 74**
Medications, number [IQR] 7 [5–10] n = 128 8 [7–11] n = 73**
B-ADL [IQR] 20 [19–20] n = 88 20 [18–20] n = 57*
ALM.height2, kg-.m-2 [IQR] 6.4 [5.6–7.4] n = 115 4.7 [4.0–5.2] n = 74**
ALM.height2 ─ Women, kg-.m-2 [IQR] 6.3 [5.6–7.1] n = 90 4.4 [4.0–5.1] n = 53**
ALM.height2 ─ Men, kg-.m-2 [IQR] 7.1 [6.1–7.8] n = 25 5.1 [4.5–5.8] n = 21**
Grip strength, kg [IQR] 25 [21–32] n = 126 17 [12–20] n = 74**
Grip strength ─ Women, kg [IQR] 22 [20–26] n = 96 14 [12–18] n = 53**
Grip strength ─ Men, kg [IQR] 40 [34–43] n = 29 24 [20–27] n = 22**
New Mobility Score [IQR] 9 [7–9] n = 127 7 [5–9] n = 71**
New mobility score–Women [IQR] 9 [7–9] n = 98 7.5 [5–9] n = 52**
New mobility score–Men [IQR] 9 [7–9] n = 29 7 [5–9] n = 19*
IQR: Values are medians and interquartile range. SD: Values are means and standard deviation.
* P0.05 or
**P0.01 is the probability for difference by Mann–Whitney–Wilcoxon test.
BMI: Body mass index. ASA score: The ASA Physical Status Classification System. Barthel ADL: Barthel activities of daily living. ALM: Appendicular lean
mass.
https://doi.org/10.1371/journal.pone.0184780.t001
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sarcopenia, 12–74% in men and 18–68% in women [6–8]. This variation in the prevalence of
sarcopenia is likely due to differences in patient groups, measurement techniques and the use
of different cut-points. The studies were from Hong Kong, Spain and Italy. Ho et al studied
Chinese patients with hip fracture and used lower cut-points for grip strength at<26kg for
men and<18kg for women. Muscle mass was determined by DXA a mean 14 days after the
fracture. In the study by Gonzalez-Montalvo et al sarcopenia was determined before surgery.
Muscle mass was determined by bioelectrical impedance and the cut-point for low muscle
mass was higher than in the present study, at<6.68 kgm-2 in women and<8.31 kgm-2 in
Fig 2. Sarcopenia and risk factors. Adjusted regression analysis using age, sex and BMI as covariates and
the analysis of vitamin D additionally adjusted for being a user of supplemental vitamin D. Estimate for age is
for 5-year increase and estimate for vitamin D is for increase of 10−5 mol.m-3 (10 nanomol/L).
https://doi.org/10.1371/journal.pone.0184780.g002
Table 2. Predictors of sarcopenia.
Univariable analysis Adjusted analysis
OR [95% CI] P-value R2 n OR [95% CI] P-value R2 n
Age, 5 years 1.4 [1.2,1.7] <0.001 0.05 202 1.4 [1.1, 1.8] 0.003 0.18 177
Female 0.7 [0.4, 1.4] 0.4 <0.01 202 0.6 [0.3, 1.4] 0.3 0.18 177
Male 1.4 [0.7, 2.6] 0.3 <0.01 202 1.6 [0.7, 3.5] 0.3 0.18 177
BMI, kg.m-2 0.8 [0.7, 0.9] <0.001 0.13 177 0.8 [0.7, 0.9] <0.001 0.18 177
NRS 2002 2.2 [1.5, 3.2] <0.001 0.08 187 1.2 [0.8, 1.9] 0.4 0.19 168
Albumin, kg.m-3 0.9 [0.8, 1.0] <0.001 0.06 172 0.9 [0.8, 1.0] 0.001 0.19 147
Vitamin D, 10−5 mol.m-3 0.9 [0.8, 1.1] 0.3 <0.01 175 1.0 [0.8, 1.1] 0.6 0.17 141
Charlson index 1.1 [0.9, 1.4] 0.3 <0.01 202 1.2 [0.9, 1.5] 0.1 0.18 177
ASA score 2.8 [1.7, 4.7] <0.001 0.06 202 2.4 [1.3, 4.3] 0.004 0.21 177
Medications 1.1 [1.0, 1.2] 0.005 0.03 201 1.2 [1.0, 1.3] 0.004 0.22 176
B-ADL 0.8 [0.6, 1.0] 0.020 0.03 145 0.8 [0.6, 1.0] 0.066 0.25 139
Sarcopenia as dependent variable in separate logistic regression analyses. Adjusted analyses are with age, gender and BMI as covariates and for vitamin D
as a predictor is additionally adjusted for being a user of supplemental vitamin D. OR: Odds ratio. CI: Confidence interval. R2: Adjusted R2. BMI: Body mass
index. ASA score: the ASA Physical Status Classification System, points. B-ADL: Barthel activities of daily living. Vitamin D 10−5 mol.m-3 (10 nmol/L).
https://doi.org/10.1371/journal.pone.0184780.t002
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men. The study by Di Monaco et al was on Italian women selected to undergo intensive reha-
bilitation after hip fracture. Di Monaco et al found that the Barthel index at the start of rehabil-
itation was lower in the group with sarcopenia, while both the study by Gonzalez-Montalvo
et al. and Di Monaco et al. reported an association between low BMI and sarcopenia [6, 8].
Compared to the patients in the Norwegian Hip Fracture Register, which covers 86–94% of
all hip fractures in Norway, the patients in our study had a mean age of 79.4 years and a mean
ASA score of 2.5, compared to 80.0 years, and an ASA score of 2.7 in the register [47]. Our
results are not generalizable for hip fracture patients from nursing homes, or patients with
severe physical or cognitive impairment. However, the relatively robust participants in our
study are more likely to benefit from intensive rehabilitation compared to frailer patients, as
found by a study by Prestmo et al on the benefit of orthogeriatric care in frail versus fit hip
fracture patients [48].
Increasing age was associated with sarcopenia and low grip strength, but not with low mus-
cle mass, which is in agreement with previous research on healthy older people [49]. There is a
significant association between low BMI and sarcopenia in other studies on sarcopenia in hip
fracture patients [6, 8], which is consistent with the finding that BMI is negatively associated
with sarcopenia, muscle mass and grip strength. Nutritional risk by NRS 2002 was associated
with sarcopenia in unadjusted analysis, but not in adjusted analysis. This is explained by how
NRS 2002 is scored, with higher scores for low BMI and age greater than 70 years. The NRS
2002 was developed as screening tool for identifying hospitalized patients likely to benefit
from nutritional interventions, and is not primarily a tool to diagnose undernutrition. Albu-
min is a biomarker of undernutrition and is a risk factor for mortality in hip fracture patients
[50]. In the present study, low albumin was associated with sarcopenia, low muscle mass and
low grip strength. Serum albumin and vitamin D are reduced in inflammatory states [51] such
as in hip fracture or surgery, and thus caution is warranted when interpreting this association.
There are numerous studies describing important associations between serum albumin and
Table 3. Muscle mass, grip strength, mobility and risk factors.
Low muscle mass Low grip strength Low mobility
OR [95% CI] n P R2 OR [95% CI] n P R2 OR [95% CI] n P R2
Age, 5 years 1.0 [0.8, 1.3] 170 0.97 0.27 1.6 [1.3, 2.0] 186 <0.001 0.15 1.5 [1.0, 2.2] 194 0.038 0.07
Female 0.2 [0.1, 0.6] 170 0.002 0.27 1.2 [0.6, 2.6] 186 0.6 0.15 0.6 [0.2, 2.2] 194 0.5 0.07
Male 5.4 [1.8, 15.8] 170 0.002 0.27 0.8 [0.4,1.7] 186 0.6 0.15 1.6 [0.4, 5.5] 194 0.5 0.07
BMI, kg.m-2 0.7 [[0.6, 0.8] 170 <0.001 0.27 0.9 [0.8, 1.0] 186 0.003 0.15 0.9 [0.8, 1.0] 194 0.2 0.07
NRS 2002 1.6 [0.8, 3.3] 163 0.2 0.27 1.1 [0.8, 1.7] 175 0.6 0.17 1.5 [0.9, 2.6] 182 0.1 0.10
Albumin, kg.m-3 0.9 [0.8, 0.9] 141 0.001 0.31 0.9 [0.9, 1.0] 154 0.006 0.17 1.0 [0.9, 1.1] 163 0.9 0.03
Vitamin D, 10−5 mol.m-3 1.0 [0.8, 1.1] 138 0.6 0.31 0.9 [0.7, 1.0] 147 0.059 0.17 0.9 [0.6, 1.2] 154 0.4 0.10
Charlson index 1.1 [0.8, 1.4] 170 0.7 0.27 1.1 [0.9, 1.4] 186 0.4 0.15 1.3 [0.9, 1.8] 194 0.2 0.09
ASA score 1.9 [1.0, 3.6] 170 0.052 0.29 1.8 [1.0, 3.0] 186 0.038 0.16 2.3 [0.9, 6.2] 194 0.09 0.10
Medications 1.0 [0.9, 1.2] 169 0.5 0.28 1.1 [1.0, 1.2] 185 0.08 0.16 1.2 [1.0, 1.5] 193 0.015 0.13
B-ADL 0.9 [0.6, 1.3] 131 0.5 0.31 0.8 [0.6,1.0] 148 0.052 0.19 0.5 [0.3, 0.7] 149 <0.001 0.34
Low muscle mass, low grip strength and low mobility as dependent variables in separate logistic regression analyses. All analyses are adjusted for age,
gender and BMI and analyses for serum vitamin D are additionally adjusted for use of supplemental vitamin D. OR: Odds ratio. CI: Confidence interval. n:
number of participants without missing values and available for analysis. P: Probability of association being random. R2: Adjusted R2. BMI: Body mass
index. ASA score: the ASA Physical Status Classification System, points. B-ADL: Barthel activities of daily living. ALM: Appendicular lean mass. Low
muscle mass7.25 kg.m-2for men and5.67 kg.m-2 for women, defined as appendicular lean mass divided by height squared. Low grip strength is 30kg
for men and20kg for women. Low mobility is NMS <5. Vitamin D 10−5 mol.m-3 (10 nmol/L).
https://doi.org/10.1371/journal.pone.0184780.t003
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clinical outcomes in patients with hip fracture, where serum albumin has been measured both
before [52], and after surgery [53]. Visser et al [54] found an increased loss of muscle mass in
participants with low serum albumin in older persons living in the community, which indi-
cates a relevant association between sarcopenia and albumin in a setting without acute in-
flammation. The finding in this study that low BMI and serum albumin are associated with
sarcopenia supports the hypothesis that nutrition and sarcopenia are associated and that nutri-
tional interventions such as supplemental protein, specific amino acids or β-hydroxy-β-
methylbutyrate can improve muscle mass, strength and physical performance [55–58]. The
present study found no association between serum vitamin D and sarcopenia, which is in
agreement with the study by Gonzalez-Montalvo et al [6] on sarcopenia in hip fracture
patients. Participants in this study had higher levels of serum vitamin D compared to other
studies on patients with hip fracture [59, 60], likely explained by the fact that half the partici-
pants used supplemental vitamin D before the fracture. The ASA score and the number of
chronic diseases are predictors of mortality after hip fracture [26]. Polypharmacy or use of
potentially inappropriate medication has been found to increase the risk of hip fracture [61],
the risk of injurious falls after hip fracture [25], and reduced mobility and grip strength in hos-
pitalized elderly [62]. In the present study, there was an association between higher ASA score,
using more medications and sarcopenia, but no association between the Charlson index and
sarcopenia. There is probably a causal relationship between comorbidities, polypharmacy and
sarcopenia. Future studies should examine the effect on sarcopenia by reducing inappropriate
polypharmacy [63]. The participants in the present study had low values on the Charlson
index with a median score of one. Many common chronic conditions, such as hypertension,
angina or osteoporosis are not counted as part of the Charlson index and it is possible that the
index does not fully capture the burden of chronic diseases.
The associations found in the present study between sex and low muscle mass, low grip
strength and reduced mobility, had wide confidence intervals. This indicates that the methods
for determining muscle mass, grip strength and mobility and risk factors were insufficiently
precise or that there were too few male participants with data on sarcopenia status in the
study, only 50 out of 202. Men have a worse prognosis after hip fracture with a 4.6-fold
increased mortality after hip fracture compared to 2.8- fold increase in women [10]. The rea-
sons for this are unclear and at odds with other research that has found a greater prevalence of
physical frailty in women [64]. Di Monaco et al [65] found that male patients with hip fracture
were more likely to have low muscle mass using sex specific cut-points, and our results agree
with this. Future studies should examine if low muscle mass in men with hip fracture can
explain the excess mortality.
Conclusion
Among previously ambulatory, community-living hip fracture patients, the prevalence of sar-
copenia was 37%. Sarcopenia was positively associated with age, ASA score and polypharmacy,
and negatively associated with BMI and albumin. By using anthropometry, grip strength and
self-reported mobility it is feasible to determine sarcopenia at the bedside in postoperative hip
fracture patients.
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